April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Retrospective Evaluation of Epithelial-On Cross-linking with Two Formulations of Riboflavin in Advanced Keratoconus
Author Affiliations & Notes
  • Eduardo J Polania
    Facultad de Medicina, Universidad de La Sabana, Bogota, Colombia
  • William Trattler
    Florida International University, MIAMI, FL
  • Roy Rubinfeld
    Florida International University, MIAMI, FL
  • Gabriela Perez
    Florida International University, MIAMI, FL
  • Jennifer Loh
    Florida International University, MIAMI, FL
  • Rosane Correa
    Florida International University, MIAMI, FL
  • Footnotes
    Commercial Relationships Eduardo Polania, None; William Trattler, CXLO (C); Roy Rubinfeld, CXLO (C); Gabriela Perez, None; Jennifer Loh, None; Rosane Correa, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 4226. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Eduardo J Polania, William Trattler, Roy Rubinfeld, Gabriela Perez, Jennifer Loh, Rosane Correa; Retrospective Evaluation of Epithelial-On Cross-linking with Two Formulations of Riboflavin in Advanced Keratoconus. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4226.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

The Purpose of this analysis was to evaluate the safety and efficacy of two formulations of riboflavin, Formulation 1 and Formulation 2, for their use in Trans-epithelial corneal collagen cross-linking. In addition, a different light intensity was used with each formulation for 30 minutes.

 
Methods
 

Patients with keratoconus who had undergone trans-epithelial CXL in one or both eyes were included in this analysis. Outcome measures included UCVA, BSCVA, and K Max at 6 months and 1 year follow up.

 
Results
 

345 eyes were assessed. For formulation 1, 177 eyes were evaluated (69.5% male) the average age was 32.3 with an average corneal loading time of 59.3 minutes, pre-op Kmax of 60.0 D and pre-op thinnest point of 447 microns. 125 eyes went through a 6 month follow up visit. The UCVA improved 1 or more lines for 46% of eyes, worsened in 10% and changed in 44%. The BSCVA improved 1 or more lines in 46% of eyes, worsened in 14% and no change in 41%. K Max average improved from pre-op to 0.56D flattening. 76 eyes with a 12 month follow up visit. The UCVA improved 1 or more lines for 58.2% of eyes, worsened in 7% and no changed in 34%. The BSCVA improved 1 or more lines in 53% of eyes, worsened in 27% and no change in 20%. K Max average improved from pre-op to 0.66D flattening. For formulation 2, 168 eyes were evaluated (70.8 % male) the average age was 32.9 with an average corneal loading time of 27.2 minutes, average pre-op Kmax of 59.6 D and average pre-op thinnest point of 448 microns. 106 eyes underwent to a 6 month follow up visit. The UCVA Improved 1 or more lines for 45% of eyes, worsened in 13% and no change in 42%. BSCVA improved 1 or more lines for 52% of eyes, worsened in 16% and no change in 31%. K Max average improved from pre-op to 0.97D flattening. 56 eyes with a 12 month follow up visit. The UCVA Improved 1 or more lines for 63.0% of eyes, worsened in 14.8% and no change in 22.2%. BSCVA improved 1 or more lines for 50.0% of eyes, worsened in 13.0% and no change in 37.0%. K Max average improved from pre-op to 0.98D flattening.

 
Conclusions
 

Epithelial-ON CXL is effective for patients with keratoconus. It Improves corneal shape, UCVA and BSCVA. A newer formulation of Riboflavin combined with a higher energy level of UV light for 30 minutes demonstrated Faster loading time, Improved flattening of Kmax and Similar improvement in UCVA and BSCVA.

   
Keywords: 574 keratoconus  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×